Showing 1911-1920 of 2050 results for "".
- CDC Updates Guidance for Public Gatheringshttps://modernod.com/news/cdc-updates-guidance-for-coronavirus-disease-2019/2477385/On Sunday, the Centers for Disease Control and Prevention (CDC) updated its guidance regarding public gatherings during the COVID-19 outbreak. The CDC now recommends that for the next 8 weeks, organizers (whether groups or individuals) cancel or postpone in-person events that consist of 50
- Clearside Biomedical Appoints Dr. George Lasezkay as President and Chief Executive Officerhttps://modernod.com/news/clearside-biomedical-appoints-dr-george-lasezkay-as-president-and-chief-executive-officer/2477375/Clearside Biomedical announced that George Lasezkay, Pharm.D., JD, has been appointed President and Chief Executive Officer. He will continue to serve on the Board of Directors. This appointment was effective March 1, 2020. “Clearside has made meaningful pro
- New Automated Method Developed for Corneal Nerve Fiber Tortuosity Analysishttps://modernod.com/news/new-automated-method-developed-for-corneal-nerve-fiber-tortuosity-analysis/2477369/The Intelligent Medical Imaging (iMED) Group at the Cixi Institute of Biomedical Engineering, Ningbo Institute of Materials Technology and Engineering (CNITECH) of the Chinese Academy of Sciences proposed a fully automated method for image-level corneal nerve fiber tortuosity estimation, contribu
- Jim Mazzo Receives the Ellis Island Medal of Honorhttps://modernod.com/news/jim-mazzo-receives-the-ellis-island-medal-of-honor/2477358/Jim Mazzo, Global President of Ophthalmic Devices with Carl Zeiss Meditec, has been chosen to receive the Ellis Island Medal of Honor in 2020. The Ellis Island Honors Society honors the importance of immigration to America’s prosperity and celebrates the contributions immigrants and their
- Long-Term Visual Acuity Unaffected by Intraocular Lens Implantation After Congenital-Cataract Surgeryhttps://modernod.com/news/long-term-visual-acuity-unaffected-by-intraocular-lens-implantation-after-congenital-cataract-surgery/2477357/Intraocular lens implantation at the time of surgery for congenital cataract during infancy neither improves nor worsens long-term visual acuity, compared with correction with contact lenses, according to findings from the Infant Aphakia Treatment Study (IATS), as
- AAO Alert: Coronavirus Update for Ophthalmologistshttps://modernod.com/news/aao-alert-coronavirus-updates-for-ophthalmologists/2477347/The Academy is sharing important ophthalmology-specific information related to the novel coronavirus, referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was previously known by the provisional name 2019-nCoV. The highly contagious virus can cause a severe respirato
- Long-Term Data Show Value of Intravenous Chemotherapy in Retinoblastomahttps://modernod.com/news/long-term-data-show-value-of-intravenous-chemotherapy-in-retinoblastoma/2477326/Intravenous chemotherapy (IVC), with intra-arterial chemotherapy (IAC) or plaque radiotherapy as needed for globe salvage, can control retinoblastoma without the need for enucleation or external beam radiotherapy (EBRT), 20-year real-world outcomes show, according to a Reuters
- Could a Hormone be Used to Treat Eye Disease?https://modernod.com/news/could-a-hormone-be-used-to-treat-eye-disease/2477314/John A. Moran Eye Center researchers continue to shed new light on the potential of the hormone erythropoietin (EPO) to treat eye disease. EPO increases red blood cell production, and is already used clinically to treat anemia. However, more recently EPO is being recognized for other properties,
- Myopia Management Focus of Pipeline Expansion for Leo Lens Pharmahttps://modernod.com/news/myopia-management-focus-of-pipeline-expansion-for-leo-lens-pharma/2477307/Leo Lens Pharma (formerly DBA as Leo Lens Technology Co.) announced it received a notice of allowance from the United States Patent and Trademark Office for a patent for the use of its proprietary MediPrint process to manufacture a contact lens capable of providing enhance
- Acucela Provides Update on Emixustat Phase 3 Clinical Trial in Patients with Stargardt Diseasehttps://modernod.com/news/acucela-provides-update-on-emixustat-phase-3-clinical-trial-in-patients-with-stargardt-disease/2477295/Acucela announced that the company has achieved over 65% subject enrollment in its ongoing phase 3 clinical trial investigating emixustat hydrochloride in patients with macular atrophy secondary to Stargardt disease. The study is a multicenter, randomized, double-masked, and placebo-contro